Imunon names industry vet Douglas Faller as CMO
New Jersey, USA-based clinical-stage biotech Imunon (Nasdaq: IMMN) has appointed Dr Douglas Faller as chief medical officer, effective February 18, 2025.
In this role Faller will lead the company’s clinical strategy including advancing Imunon’s lead program IMNN-001 for the treatment of newly diagnosed advanced ovarian cancer, which is on track to enter a Phase III pivotal trial in the first quarter of 2025.
Last year, Imunon released Phase II trial results, that showed a median 11-month improvement in overall survival (OS) in all advanced ovarian cancer patients treated with IMNN-001. The median overall survival increased to 15.7 months in patients who received ≥3 doses of IMNN-001 (91% of the intent to treat population).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze